Azacitidine in lower-risk myelodysplastic syndromes.

  title={Azacitidine in lower-risk myelodysplastic syndromes.},
  author={Valeria Santini},
  journal={Leukemia research},
  volume={33 Suppl 2},
Azacitidine is the first agent to significantly prolong overall survival (OS) compared with conventional care regimens in patients with higher-risk myelodysplastic syndromes (MDS). Here, we review currently available data on azacitidine treatment in lower-risk MDS. In a phase III study, a subset of patients with lower-risk MDS treated with azacitidine achieved an overall response rate (ORR) of 60% and a longer median OS compared with supportive care (44 vs 27 months). In a phase II study… CONTINUE READING